No Data
No Data
Shineco's Shineco Life Sciences Group Hong Kong Limited Subsidiary Entered Share Purchase Agreement To Acquire 51% Equity Interest In InfiniClone Limited; Will Pay $19,895,600 In Cash And Issue And Transfer 3,450,000 Shares To Seller
Express News | Shineco Inc - Deal Valued at $19,895,600 Plus 3,450,000 Shares
Express News | Shineco Inc - to Acquire 51% Equity Interest in Infiniclone
Express News | Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company
Shangao acquires a cutting-edge stem cell company in Singapore.
Opening new spaces in regenerative medicine Peking, April 23, 2025 /PR Newswire/ -- SHINECO (hereinafter referred to as "SHINECO" or "the Company"; Nasdaq trading code: SISI; a manufacturer of innovative diagnostic medical products and related Medical Devices) announced today that its subsidiary SHINECO Life Sciences Group Hong Kong Limited (hereinafter referred to as "SHINECO Life Sciences") has signed a Stock Purchase Agreement (hereinafter referred to as "the Agreement") with Dr. Lin Chia-Ming ("the Seller") on April 22, 2025, to acquire the Stocks held by him in InfiniClone Limited (hereinafter referred to as "
Express News | Shares of Companies Within the Broader Consumer Staples Sector Are Trading Lower Amid Overall Market Weakness